查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
亞太細胞與基因治療生物製造市場：2022-2031
市場調查報告書
商品編碼
1379167

亞太細胞與基因治療生物製造市場：2022-2031

Asia-Pacific Cell and Gene Therapy Biomanufacturing Market - Analysis and Forecast, 2022-2031
出版日期: | 出版商: BIS Research | 英文 108 Pages | 商品交期: 1-5個工作天內

價格

預計亞太細胞和基因治療生物製造市場規模將從2022年的19.6億美元成長到2031年的86億美元，預測期內年複合成長率為17.88%。

由於已經過核准的治療方法數量不斷增加以及基礎設施需求不斷增加，預計該市場將會成長。此外，基因和細胞治療適應症的不斷擴大需要廣泛的生物製造能力。

亞太地區的細胞和基因治療生物製造業正進入快速擴張和變革的時期。由於已經過核准藥品數量不斷增加和基礎設施需求不斷增加，該地區有望成為尖端生物製造中心。基因和細胞治療目標適應症的擴大推動了該地區對大型生物製造設施的巨大需求。由於政府、製藥公司和學術機構的持續投資，幫助開發新的救命藥物療法，該市場也在不斷成長。

本報告調查了亞太地區的細胞和基因治療生物製造市場，提供了市場概況，分析了市場成長的各種影響因素、法律制度、市場規模趨勢和預測以及各個細分市場和地區。/編譯主要國家詳細分析、競爭形勢、主要企業分析等

主要市場統計數據
預測期 2022-2031
2022年評估 19.6億美元
2031年預測 86億美元
年複合成長率 17.88%

市場區隔：

細分 1：按產品類型

  • 消耗品
  • 裝置
  • 軟體解決方案

細分 2：依最終用戶分類

  • 生命科學公司
  • CRO
  • CMO
  • 細胞庫

細分 3：按國家/地區

  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲/紐西蘭
  • 亞太地區其他地區

主要企業：

  • WuXi AppTec

目錄

第1章 市場

  • 產業展望
    • 市場概況與生態系統
    • 主要趨勢
    • 機會評估
    • 法律規範
    • 產品基準評效
    • 專利分析
    • 商業模式分析
    • 研發線產品
    • 技術介紹矩陣
    • 資金籌措場景
    • 關鍵成功因素
  • COVID-19 對細胞和基因治療生物製造市場的影響
  • 俄羅斯-烏克蘭戰爭對細胞和基因治療生物製造市場的影響

第2章 亞太地區

  • 亞太地區
    • 主要發現和機會評估
    • 市場動態
    • 市場規模/預測分析

第3章 市場：競爭基準化分析/公司簡介

  • 競爭基準化分析
  • 企業市場占有率分析
  • 公司簡介
Product Code: BHL1492SS

“The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Expected to Reach $8.60 Billion by 2031.”

KEY MARKET STATISTICS
Forecast Period2022 - 2031
2022 Evaluation$1.96 Billion
2031 Forecast$8.60 Billion
CAGR17.88%

Introduction to Asia-Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market

The Asia Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market is expected to grow at a CAGR of 17.88% from $1.96 Billion in 2022 to $8.60 Billion in 2031 in the forecasted period of 2022-2031. APAC cell and gene therapy biomanufacturing industry is expected to grow due in part to the increasing number of authorized treatments and growing infrastructural requirements. Extensive biomanufacturing capabilities are also required due to the expanding target indications for gene and cell treatments.

Market Introduction

The industry for cell and gene therapy biomanufacturing in Asia-Pacific (APAC) is about to undergo a period of rapid expansion and change. This area is set to become a center for state-of-the-art biomanufacturing due to the rise of authorized medicines and the rising requirements for infrastructure. A significant need for large-scale biomanufacturing facilities in Asia-Pacific is being driven by the broadening range of target indications for gene and cell therapies. The APAC market for cell and gene therapy biomanufacturing is growing as a result of continued investment in this area by governments, pharmaceutical corporations, and academic organizations, which is helping to develop novel and perhaps life-saving medical therapies. In addition to seeing the creation of cutting-edge treatments, this area is essential to the world's biomanufacturing industry.

Market Segmentation:

Segmentation 1: by Product Type

  • Consumables
  • Equipment
  • Software Solutions

Segmentation 2: by End User

  • Life Science Companies
  • Contract Research Organizations (CROs)
  • Contract Manufacturing Organizations (CMOs)
  • Cell Banks

Segmentation 3: by Country

  • China
  • Japan
  • India
  • South Korea
  • Australia/New Zealand
  • Rest-of-Asia-Pacific

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific Cell and Gene Therapy Biomanufacturing Market:

  • Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
  • Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
  • Robust Clinical Pipeline Creating a Demand for Biomanufacturing Infrastructure

The market is expected to face some limitations as well due to the following challenges:

  • High Set-Up Cost of Biomanufacturing Facilities

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy biomanufacturing market (by product type) has been segmented into consumables, equipment, and software solutions.

Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for upstream processing, harvesting, downstream processing, and other applications. Various companies are providing consumables and equipment aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current cell and gene therapy biomanufacturing market.

Competitive Strategy: Key players in the APAC cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • WuXi AppTec

Table of Contents

1 Markets

  • 1.1 Industry Outlook
    • 1.1.1 Market Overview and Ecosystem
    • 1.1.2 Key Trends
      • 1.1.2.1 Biomanufacturing 4.0
      • 1.1.2.2 Growing Single-Use Technology Market Penetration
      • 1.1.2.3 Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
      • 1.1.2.4 Leveraging Various Key Strategies to Diversify the Product Portfolio
    • 1.1.3 Opportunity Assessment
    • 1.1.4 Regulatory Framework
    • 1.1.5 Product Benchmarking
      • 1.1.5.1 Product Benchmarking (by Product Type)
      • 1.1.5.2 Comparative Analysis (by Equipment)
    • 1.1.6 Patent Analysis
      • 1.1.6.1 Patent Analysis (by Year)
      • 1.1.6.2 Patent Analysis (by Country)
      • 1.1.6.3 Awaited Technologies
    • 1.1.7 Business Model Analysis
    • 1.1.8 Pipeline Products
    • 1.1.9 Technology Adoption Matrix
    • 1.1.10 Funding Scenario
    • 1.1.11 Key Success Factors
  • 1.2 Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
    • 1.2.1 Recommendations to Manufacturers
  • 1.3 Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market

2 Asia-Pacific

  • 2.1 Asia-Pacific
    • 2.1.1 Key Findings and Opportunity Assessment
    • 2.1.2 Market Dynamics
      • 2.1.2.1 Impact Analysis
    • 2.1.3 Sizing and Forecast Analysis
      • 2.1.3.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
      • 2.1.3.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
        • 2.1.3.3.1 China
          • 2.1.3.3.1.1 China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
          • 2.1.3.3.1.2 China Cell and Gene Therapy Biomanufacturing Market (by End User)
        • 2.1.3.3.2 Japan
          • 2.1.3.3.2.1 Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
          • 2.1.3.3.2.2 Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
        • 2.1.3.3.3 India
          • 2.1.3.3.3.1 India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
          • 2.1.3.3.3.2 India Cell and Gene Therapy Biomanufacturing Market (by End User)
        • 2.1.3.3.4 South Korea
          • 2.1.3.3.4.1 South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
          • 2.1.3.3.4.2 South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
        • 2.1.3.3.5 Australia/New Zealand
          • 2.1.3.3.5.1 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
          • 2.1.3.3.5.2 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
        • 2.1.3.3.6 Rest-of-Asia-Pacific
          • 2.1.3.3.6.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
          • 2.1.3.3.6.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)

3 Markets - Competitive Benchmarking and Company Profiles

  • 3.1 Competitive Benchmarking
    • 3.1.1 Competitive Landscape
      • 3.1.1.1 Segmental Growth Share Matrix
        • 3.1.1.1.1 Growth Share Analysis (by Product Type)
        • 3.1.1.1.2 Growth Share Analysis (by Application)
      • 3.1.1.2 Competitive Index (Unmet Needs and Innovations)
      • 3.1.1.3 Company Position Analysis
      • 3.1.1.4 Key Strategies and Developments
        • 3.1.1.4.1 Funding Activities
        • 3.1.1.4.2 New Offerings
        • 3.1.1.4.3 Mergers and Acquisitions
        • 3.1.1.4.4 Partnerships, Alliances, and Business Expansions
        • 3.1.1.4.5 Key Development Analysis
  • 3.2 Company Share Analysis
  • 3.3 Company Profiles
    • 3.3.1 WuXi AppTec
      • 3.3.1.1 Company Overview
      • 3.3.1.2 Role of WuXi AppTec in the Cell and Gene Therapy Biomanufacturing Market
      • 3.3.1.3 Major Product: Key Specifications
      • 3.3.1.4 Customers and Competitions/Opportunities
        • 3.3.1.4.1 Key Competitors
      • 3.3.1.5 Analyst Perspective

List of Figures

  • Figure 1: Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 2: Cell and Gene Therapy Biomanufacturing Market: Drivers, Restraints, and Opportunities
  • Figure 3: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Impact Analysis
  • Figure 4: Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
  • Figure 5: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Region), $Billion, 2021 and 2031
  • Figure 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Share of Key Developments and Strategies (by Category), January 2020-January 2023
  • Figure 7: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Segmentation
  • Figure 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market: Research Methodology
  • Figure 9: Primary Research Methodology
  • Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 11: Top-Down Approach (Segment-Wise Analysis)
  • Figure 12: Market Overview and Ecosystem
  • Figure 13: Insights on Strategies Adopted by Major Players, January 2020-January 2023
  • Figure 14: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Trends, Market Shift, 2022-2031
  • Figure 15: TcBuster vs. Viral Gene Engineering Technology, Comparative Analysis
  • Figure 16: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Year), January 2020-December 2022
  • Figure 17: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Country), January 2020-December 2022
  • Figure 18: Anticipated Regulatory Milestones in 2023
  • Figure 19: Anticipated Regulatory Approval, U.S. and EU, 2023
  • Figure 20: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Technology Adoption Matrix
  • Figure 21: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Success Factors
  • Figure 22: Impact of COVID-19 on CGT Developmental Activities
  • Figure 23: Progress in Cell and Gene Therapy (CGT) Regulation during COVID-19
  • Figure 24: Ways to Increase Supply Chain and Manufacturing
  • Figure 25: Impact on Biopharmaceutical Industries
  • Figure 26: Cell and Gene Therapy Biomanufacturing Market Share (by Region)
  • Figure 27: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
  • Figure 28: Ongoing Clinical Trials, Asia-Pacific (by Country)
  • Figure 29: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
  • Figure 30: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 31: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
  • Figure 32: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
  • Figure 33: China Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 34: China Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
  • Figure 35: China Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
  • Figure 36: Japan Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 37: Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
  • Figure 38: Japan Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
  • Figure 39: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, India, 2020 vs. 2040
  • Figure 40: India Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 41: India Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
  • Figure 42: India Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
  • Figure 43: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, South Korea, 2020 vs. 2040
  • Figure 44: South Korea Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 45: South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
  • Figure 46: South Korea Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
  • Figure 47: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 48: New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
  • Figure 49: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
  • Figure 50: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
  • Figure 51: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
  • Figure 52: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
  • Figure 53: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), 2021-2031
  • Figure 54: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Application), 2021-2031
  • Figure 55: Competitive Index, Unmet Needs, Solutions, and Impacts
  • Figure 56: Company Position Analysis
  • Figure 57: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Total Number of Key Developments, January 2020-January 2023
  • Figure 58: Funding Activities, January 2020-January 2023
  • Figure 59: New Offerings, January 2020-September 2023
  • Figure 60: Mergers and Acquisitions, January 2020-January 2023
  • Figure 61: Partnerships, Alliances, and Business Expansion Activities, January 2020-January 2023
  • Figure 62: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Company Share Analysis, % Share, 2021
  • Figure 63: WuXi AppTec: Product Portfolio

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Single-Use and Stainless-Steel Facilities, Comparative Analysis
  • Table 3: Asia-Pacific Regulatory Scenario: Cell and Gene Therapy Biomanufacturing Market
  • Table 4: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), Product Benchmarking
  • Table 5: Comparative Analysis of Various Bioreactors Offered by Key Players
  • Table 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Awaited Technologies
  • Table 7: Business Models, Key Features
  • Table 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
  • Table 9: Approved Cell and Gene Therapies, Japan
  • Table 10: Ongoing Industry Sponsored Cell and Gene Therapy Clinical Trials
  • Table 11: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Development Analysis, January 2020-January 2023